chlorpromazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
621 50-53-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorpromazine
  • 2-Chloropromazine
  • chlordelazin
  • chlorderazin
  • thorazine
  • contomin
  • chlorpromazine hydrochloride
  • chlorpromazine HCl
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
  • Molecular weight: 318.86
  • Formula: C17H19ClN2S
  • CLOGP: 5.50
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.88
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.10 g P
0.30 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 52.37 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 11 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.230 High 0.85
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.940 High 0.85
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 16.634 10^-6 cm/s High 0.85
dh-clint Dog hepatocyte intrinsic clearance 108.893 uL/min/10^6 cells High 0.85
dppb Dog plasma protein binding (% unbound) 2.220 % High 0.85
fcs-ppb Fetal calf serum protein binding (% unbound) 5.070 % High 0.85
herg hERG pIC50 5.902 pIC50 High 0.85
hh-clint Human hepatocyte intrinsic clearance 23.227 uL/min/10^6 cells High 0.85
hlm-clint Human liver microsomal intrinsic clearance 29.992 uL/min/mg protein High 0.85
hppb Human plasma protein binding (% unbound) 2.260 % High 0.85
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,INSR,ITK,JAK1,JAK2,JAK3,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 57
kinase-selectivity-class PDK4 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.603 High 0.85
mh-clint Mouse hepatocyte intrinsic clearance 212.324 High 0.85
mppb Mouse plasma protein binding (% unbound) 2.550 High 0.85
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.213 High 0.85
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 10.300 % High 0.85
rh-clint Rat hepatocyte intrinsic clearance 273.527 uL/min/10^6 cells High 0.85
rh-fuinc Rat hepatocyte fraction unbound in incubation 14.520 % High 0.85
rppb Rat plasma protein binding (% unbound) 2.630 % High 0.85
solubility-dd Solubility at pH 7.4 in DMSO 374.111 uM High 0.85

Approvals:

DateAgencyCompanyOrphan
Sept. 18, 1957 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 266.95 24.45 150 10868 82197 90535232
Toxicity to various agents 257.09 24.45 239 10779 287607 90329822
Sopor 243.71 24.45 97 10921 24547 90592882
Neuroleptic malignant syndrome 239.33 24.45 84 10934 15012 90602417
Overdose 174.40 24.45 148 10870 157561 90459868
Coma 174.22 24.45 109 10909 72523 90544906
Electrocardiogram QT prolonged 147.28 24.45 98 10920 72358 90545071
Catatonia 136.80 24.45 44 10974 6012 90611417
Tardive dyskinesia 122.02 24.45 47 10971 10883 90606546
Poisoning deliberate 119.43 24.45 52 10966 16434 90600995
Suicide attempt 118.22 24.45 87 10931 75312 90542117
Aggression 115.56 24.45 59 10959 26609 90590820
Agitation 106.49 24.45 78 10940 67020 90550409
Intentional overdose 103.46 24.45 88 10930 93746 90523683
Intentional self-injury 96.43 24.45 54 10964 29280 90588149
Somnolence 93.63 24.45 121 10897 208963 90408466
Mania 84.57 24.45 39 10979 14085 90603344
Sedation 83.28 24.45 59 10959 48112 90569317
Hallucination, auditory 77.01 24.45 38 10980 15937 90601492
Psychomotor hyperactivity 75.53 24.45 35 10983 12778 90604651
Completed suicide 74.57 24.45 90 10928 144968 90472461
Gliosis 73.40 24.45 16 11002 479 90616950
Hepatic cytolysis 73.05 24.45 46 10972 30870 90586559
Parkinsonism 72.42 24.45 35 10983 14030 90603399
Dystonia 72.24 24.45 37 10981 16782 90600647
Altered state of consciousness 72.22 24.45 46 10972 31486 90585943
Polyserositis 68.51 24.45 16 11002 657 90616772
Pouchitis 68.41 24.45 16 11002 661 90616768
Pneumonia aspiration 68.13 24.45 49 10969 40891 90576538
Tremor 65.95 24.45 87 10931 153086 90464343
Psychotic disorder 65.23 24.45 43 10975 31187 90586242
Delusion 63.98 24.45 32 10986 13808 90603621
Head titubation 63.12 24.45 17 11001 1251 90616178
Polydipsia 61.16 24.45 22 10996 4209 90613220
Myoclonus 59.51 24.45 34 10984 19134 90598295
Mental disorder 59.14 24.45 41 10977 32277 90585152
Premature menopause 57.70 24.45 16 11002 1313 90616116
Apraxia 57.55 24.45 18 11000 2244 90615185
Drug interaction 56.70 24.45 112 10906 276341 90341088
Disorganised speech 56.45 24.45 17 11001 1868 90615561
Depressed level of consciousness 54.44 24.45 55 10963 72729 90544700
Ovarian failure 54.34 24.45 16 11002 1627 90615802
Antiphospholipid syndrome 53.31 24.45 17 11001 2257 90615172
Seizure 52.72 24.45 78 10940 152551 90464878
Cardiac arrest 50.49 24.45 63 10955 104872 90512557
Hypothermia 49.35 24.45 28 10990 15547 90601882
Tachycardia 48.00 24.45 76 10942 157597 90459832
Stereotypy 47.26 24.45 11 11007 445 90616984
Somatic symptom disorder 46.41 24.45 17 11001 3424 90614005
Grandiosity 45.88 24.45 10 11008 299 90617130
Salivary hypersecretion 44.93 24.45 22 10996 9070 90608359
Mutism 44.69 24.45 14 11004 1755 90615674
Proctectomy 43.86 24.45 9 11009 200 90617229
Dyspnoea 43.19 24.45 27 10991 880928 89736501
Wrong patient received product 42.57 24.45 16 11002 3461 90613968
Hepatocellular injury 42.19 24.45 32 10986 28926 90588503
Irritability 40.40 24.45 34 10984 35628 90581801
Torsade de pointes 39.43 24.45 24 10994 15158 90602271
Arthralgia 39.35 24.45 23 10995 778499 89838930
Venous thrombosis limb 39.03 24.45 15 11003 3447 90613982
Cardio-respiratory arrest 38.83 24.45 43 10975 63097 90554332
Miosis 38.24 24.45 20 10998 9464 90607965
Suicidal ideation 38.20 24.45 46 10972 73809 90543620
Behaviour disorder 38.11 24.45 16 11002 4619 90612810
Premature delivery 37.94 24.45 34 10984 38728 90578701
Pain in extremity 37.92 24.45 5 11013 450524 90166905
Dyskinesia 37.66 24.45 33 10985 36501 90580928
Abnormal behaviour 37.44 24.45 27 10991 22601 90594828
Cognitive disorder 37.16 24.45 44 10974 69363 90548066
Swelling 36.87 24.45 4 11014 419054 90198375
Abdominal discomfort 36.34 24.45 7 11011 477321 90140108
Hypotension 36.27 24.45 104 10914 325293 90292136
Alopecia 36.17 24.45 8 11010 495063 90122366
Vasoconstriction 35.43 24.45 10 11008 875 90616554
Cardiac tamponade 35.12 24.45 16 11002 5616 90611813
Treatment noncompliance 34.90 24.45 37 10981 51690 90565739
Hypotonia neonatal 34.80 24.45 11 11007 1419 90616010
Encephalopathy 34.54 24.45 35 10983 46409 90571020
Hallucinations, mixed 34.43 24.45 16 11002 5873 90611556
Hypersensitivity 33.92 24.45 7 11011 454670 90162759
Peripheral swelling 33.78 24.45 5 11013 413101 90204328
Gaze palsy 33.31 24.45 11 11007 1630 90615799
Eosinophilic myocarditis 33.23 24.45 9 11009 676 90616753
Epileptic encephalopathy 33.10 24.45 8 11010 381 90617048
Pain 32.84 24.45 44 10974 996297 89621132
Lactate pyruvate ratio increased 32.20 24.45 6 11012 79 90617350
Rash 31.85 24.45 30 10988 796070 89821359
Movement disorder 31.50 24.45 27 10991 28992 90588437
Drug intolerance 31.18 24.45 8 11010 447583 90169846
Psychomotor skills impaired 30.80 24.45 12 11006 2860 90614569
Vertigo 30.55 24.45 40 10978 69771 90547658
Ileostomy closure 29.75 24.45 7 11011 297 90617132
Self-injurious ideation 29.53 24.45 12 11006 3191 90614238
Violence-related symptom 29.51 24.45 8 11010 603 90616826
Tonic clonic movements 28.88 24.45 10 11008 1712 90615717
Sinusitis 28.40 24.45 4 11014 343084 90274345
Dysarthria 28.27 24.45 34 10984 54448 90562981
Rhabdomyolysis 28.27 24.45 33 10985 51223 90566206
Muscle rigidity 28.18 24.45 19 10999 14290 90603139
Blood citric acid increased 27.83 24.45 5 11013 53 90617376
Pseudohallucination 27.81 24.45 6 11012 171 90617258
Illusion 27.79 24.45 9 11009 1255 90616174
Fatigue 27.13 24.45 63 10955 1153960 89463469
Peritonitis 27 24.45 21 10997 19684 90597745
Anger 26.50 24.45 18 11000 13702 90603727
Blood creatine phosphokinase increased 25.95 24.45 26 10992 33997 90583432
Extrapyramidal disorder 25.94 24.45 19 10999 16284 90601145
Onychophagia 25.86 24.45 5 11013 81 90617348
Poisoning 24.82 24.45 18 11000 15199 90602230
Newborn persistent pulmonary hypertension 24.70 24.45 6 11012 292 90617137
Withdrawal syndrome 24.53 24.45 21 10997 22503 90594926

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 398.24 19.12 176 13827 21296 42586036
Extrapyramidal disorder 267.54 19.12 123 13880 16289 42591043
Psychotic disorder 245.45 19.12 140 13863 29068 42578264
Delusion of grandeur 189.37 19.12 55 13948 1941 42605391
Emotional poverty 171.11 19.12 41 13962 671 42606661
Hallucination, auditory 165.81 19.12 86 13917 14778 42592554
Rhinalgia 158.19 19.12 47 13956 1797 42605535
Affective disorder 147.42 19.12 60 13943 5900 42601432
Lymphocyte count abnormal 141.96 19.12 45 13958 2142 42605190
Tardive dyskinesia 122.57 19.12 55 13948 6869 42600463
Neutrophil count increased 122.43 19.12 78 13925 19726 42587606
Catatonia 121.53 19.12 53 13950 6186 42601146
Decreased eye contact 109.74 19.12 27 13976 496 42606836
Oppositional defiant disorder 107.34 19.12 27 13976 545 42606787
Sedation 107.01 19.12 85 13918 30390 42576942
Psychomotor hyperactivity 106.92 19.12 58 13945 10900 42596432
Suicide attempt 106.05 19.12 101 13902 45999 42561333
Overdose 105.15 19.12 150 13853 105114 42502218
Aggression 98.25 19.12 95 13908 44068 42563264
Bruxism 90.49 19.12 32 13971 2137 42605195
SARS-CoV-2 test positive 89.82 19.12 47 13956 8213 42599119
Homicidal ideation 89.76 19.12 34 13969 2760 42604572
Parkinsonism 86.67 19.12 50 13953 10573 42596759
Foetal disorder 81.77 19.12 25 13978 1054 42606278
Seizure 76.73 19.12 140 13863 120421 42486911
Neutropenia 72.02 19.12 184 13819 199247 42408085
Schizophrenia 71.34 19.12 44 13959 10506 42596826
Dyskinesia 70.81 19.12 62 13941 25328 42582004
Neutropenia neonatal 68.38 19.12 21 13982 899 42606433
Leukopenia 66.59 19.12 101 13902 74645 42532687
Priapism 65.53 19.12 35 13968 6372 42600960
Lymphocyte count decreased 64.05 19.12 61 13942 27748 42579584
Salivary hypersecretion 60.01 19.12 40 13963 10903 42596429
Intentional self-injury 58.98 19.12 45 13958 15157 42592175
Spasmodic dysphonia 56.78 19.12 16 13987 505 42606827
Drug withdrawal syndrome neonatal 56.09 19.12 28 13975 4433 42602899
Foetal exposure during pregnancy 55.58 19.12 73 13930 47238 42560094
Treatment noncompliance 55.28 19.12 65 13938 37607 42569725
Antipsychotic drug level increased 54.90 19.12 28 13975 4638 42602694
Suicidal ideation 54.56 19.12 73 13930 48088 42559244
Dystonia 54.38 19.12 40 13963 12750 42594582
Arthralgia 49.56 19.12 5 13998 205233 42402099
Choreoathetosis 48.70 19.12 17 13986 1092 42606240
Trismus 48.15 19.12 22 13981 2862 42604470
Alopecia 47.14 19.12 53 13950 29223 42578109
Dyspnoea 46.83 19.12 46 13957 442575 42164757
Delirium 46.79 19.12 71 13932 52448 42554884
Crying 46.64 19.12 28 13975 6366 42600966
Myocarditis 46.39 19.12 43 13960 18895 42588437
Hyperkinesia 44.72 19.12 19 13984 2079 42605253
Agitation 43.81 19.12 77 13926 64237 42543095
Sopor 42.45 19.12 35 13968 13167 42594165
Persecutory delusion 40.81 19.12 21 13982 3543 42603789
Coordination abnormal 40.74 19.12 28 13975 8022 42599310
Tachycardia 40.32 19.12 97 13906 100990 42506342
Dextrocardia 38.84 19.12 8 13995 62 42607270
Mucosal inflammation 38.78 19.12 63 13940 49311 42558021
Pain 38.75 19.12 16 13987 244832 42362500
Blood creatine phosphokinase increased 38.40 19.12 62 13941 48276 42559056
Irritability 37.12 19.12 46 13957 28082 42579250
Dyspepsia 36.96 19.12 56 13947 41296 42566036
Toxicity to various agents 36.93 19.12 161 13842 228975 42378357
Intestinal obstruction 36.78 19.12 45 13958 27113 42580219
Foetal alcohol syndrome 36.66 19.12 8 13995 84 42607248
Congenital cerebrovascular anomaly 35.54 19.12 6 13997 12 42607320
Incorrect dose administered 35.52 19.12 63 13940 52911 42554421
Pruritus 33.87 19.12 10 13993 188761 42418571
Social anxiety disorder 33.33 19.12 11 13992 595 42606737
Pain in extremity 33.09 19.12 5 13998 150599 42456733
Antisocial personality disorder 32.95 19.12 7 13996 64 42607268
Affect lability 32.89 19.12 19 13984 4025 42603307
Schizoaffective disorder 32.80 19.12 15 13988 1955 42605377
Speech disorder 32.75 19.12 44 13959 29077 42578255
Therapy non-responder 31.42 19.12 60 13943 53299 42554033
Rhabdomyolysis 31.24 19.12 75 13928 77944 42529388
Intentional product misuse 30.94 19.12 65 13938 61835 42545497
Premature baby 30.77 19.12 38 13965 23115 42584217
Cellulitis 30.00 19.12 64 13939 61521 42545811
Manic symptom 29.91 19.12 8 13995 207 42607125
Hallucination, tactile 29.66 19.12 10 13993 578 42606754
Delusion 29.59 19.12 30 13973 14704 42592628
Insomnia 28.01 19.12 94 13909 118159 42489173
Streptococcal infection 27.93 19.12 20 13983 6112 42601220
Cerebral amyloid angiopathy 27.65 19.12 8 13995 278 42607054
Neutrophil count decreased 27.61 19.12 63 13940 63352 42543980
Mood altered 27.54 19.12 25 13978 10693 42596639
Low birth weight baby 27.12 19.12 24 13979 9931 42597401
Agranulocytosis 26.71 19.12 41 13962 30571 42576761
Hiccups 26.69 19.12 26 13977 12145 42595187
Floppy iris syndrome 26.67 19.12 8 13995 316 42607016
Mental impairment 26.43 19.12 26 13977 12291 42595041
Poor feeding infant 26.16 19.12 10 13993 832 42606500
Sinus tachycardia 26.01 19.12 33 13970 20620 42586712
Mania 25.93 19.12 24 13979 10523 42596809
Alcohol abuse 25.13 19.12 16 13987 4033 42603299
Muscle rigidity 25.03 19.12 25 13978 12034 42595298
Torticollis 24.61 19.12 11 13992 1359 42605973
Drug abuse 24.56 19.12 83 13920 104688 42502644
Depressed mood 24.28 19.12 34 13969 23350 42583982
Somnolence 24.12 19.12 101 13902 141004 42466328
Dysphemia 24.09 19.12 12 13991 1890 42605442
Headache 23.97 19.12 26 13977 239343 42367989
Paranoia 23.61 19.12 26 13977 14000 42593332
Respiratory depression 23.52 19.12 30 13973 18838 42588494
Drug interaction 23.47 19.12 159 13844 266840 42340492
Drug withdrawal syndrome 23.37 19.12 32 13971 21517 42585815
Hyperprolactinaemia 22.84 19.12 12 13991 2111 42605221
Rash 22.67 19.12 35 13968 276919 42330413
Encephalopathy 22.53 19.12 45 13958 41288 42566044
Poor quality sleep 22.28 19.12 21 13982 9419 42597913
Intentional overdose 22.26 19.12 51 13952 51405 42555927
Acanthosis nigricans 22.12 19.12 6 13997 164 42607168
Drug resistance 22.02 19.12 40 13963 34208 42573124
Psychomotor retardation 21.55 19.12 15 13988 4384 42602948
Myalgia 21.54 19.12 3 14000 96077 42511255
Anaemia 21.46 19.12 37 13966 280241 42327091
Pneumonia aspiration 20.97 19.12 49 13954 50029 42557303
Faecaloma 20.95 19.12 17 13986 6253 42601079
Long QT syndrome 20.87 19.12 13 13990 3154 42604178
Leukocytosis 20.77 19.12 36 13967 29672 42577660
Faecal vomiting 20.72 19.12 8 13995 684 42606648
Neoplasm progression 20.09 19.12 35 13968 28965 42578367
Orthostatic hypotension 20.03 19.12 36 13967 30534 42576798
Oedema peripheral 19.78 19.12 10 13993 136066 42471266
Electroconvulsive therapy 19.65 19.12 4 13999 29 42607303
Hyperammonaemia 19.53 19.12 18 13985 7848 42599484

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 651.78 18.29 250 22517 33809 110532723
Extrapyramidal disorder 305.50 18.29 139 22628 28728 110537804
Psychotic disorder 281.54 18.29 158 22609 50779 110515753
Overdose 273.05 18.29 286 22481 233508 110333024
Catatonia 259.93 18.29 95 22672 11205 110555327
Sopor 251.14 18.29 131 22636 36415 110530117
Tardive dyskinesia 250.02 18.29 97 22670 13482 110553050
Hallucination, auditory 238.65 18.29 114 22653 26283 110540249
Toxicity to various agents 232.06 18.29 380 22387 480175 110086357
Drug abuse 219.57 18.29 224 22543 177187 110389345
Aggression 204.57 18.29 136 22631 59074 110507458
Delusion of grandeur 203.25 18.29 54 22713 2206 110564326
Suicide attempt 202.91 18.29 169 22598 103225 110463307
Psychomotor hyperactivity 184.59 18.29 88 22679 20189 110546343
Sedation 177.83 18.29 133 22634 69550 110496982
Emotional poverty 159.04 18.29 38 22729 1002 110565530
Affective disorder 157.54 18.29 66 22701 11175 110555357
Lymphocyte count abnormal 153.59 18.29 44 22723 2382 110564150
Coma 153.36 18.29 153 22614 117716 110448816
Parkinsonism 150.88 18.29 79 22688 22108 110544424
Seizure 143.52 18.29 201 22566 220984 110345548
Rhinalgia 140.73 18.29 46 22721 3883 110562649
Intentional self-injury 134.16 18.29 88 22679 37341 110529191
Agitation 127.64 18.29 136 22631 112915 110453617
Neutrophil count increased 123.05 18.29 81 22686 34571 110531961
Oppositional defiant disorder 122.54 18.29 27 22740 491 110566041
Dystonia 118.48 18.29 71 22696 25734 110540798
Dyskinesia 117.62 18.29 92 22675 51354 110515178
Somnolence 114.26 18.29 213 22554 297236 110269296
Salivary hypersecretion 112.69 18.29 60 22707 17361 110549171
Decreased eye contact 112.25 18.29 28 22739 887 110565645
Intentional overdose 110.03 18.29 136 22631 132365 110434167
Electrocardiogram QT prolonged 107.26 18.29 122 22645 108838 110457694
Poisoning deliberate 106.97 18.29 67 22700 26264 110540268
Homicidal ideation 92.79 18.29 33 22734 3594 110562938
Pneumonia aspiration 88.63 18.29 96 22671 81137 110485395
Dyspnoea 85.78 18.29 62 22705 1106810 109459722
Arthralgia 85.77 18.29 27 22740 779605 109786927
Suicidal ideation 85.44 18.29 101 22666 93836 110472696
Altered state of consciousness 84.65 18.29 80 22687 57546 110508986
Completed suicide 82.52 18.29 165 22602 242216 110324316
Mania 82.18 18.29 52 22715 20744 110545788
Tachycardia 81.65 18.29 158 22609 226487 110340045
Priapism 80.74 18.29 34 22733 5827 110560705
Bruxism 79.07 18.29 32 22735 4962 110561570
Drug interaction 78.81 18.29 254 22513 499929 110066603
Pain 78.62 18.29 50 22717 954905 109611627
Neutropenia 77.87 18.29 210 22557 374410 110192122
SARS-CoV-2 test positive 76.20 18.29 46 22721 16889 110549643
Delusion 75.87 18.29 52 22715 23703 110542829
Joint swelling 74.83 18.29 4 22763 442841 110123691
Blood creatine phosphokinase increased 73.90 18.29 83 22684 72994 110493538
Myocarditis 73.60 18.29 56 22711 29999 110536533
Treatment noncompliance 72.27 18.29 82 22685 72908 110493624
Antipsychotic drug level increased 71.72 18.29 33 22734 6982 110559550
Leukopenia 70.59 18.29 117 22650 148674 110417858
Rhabdomyolysis 70.07 18.29 104 22663 120297 110446235
Pain in extremity 69.77 18.29 9 22758 487109 110079423
Lymphocyte count decreased 68.37 18.29 71 22696 57172 110509360
Infusion related reaction 62.69 18.29 4 22763 381158 110185374
Spasmodic dysphonia 62.63 18.29 16 22751 559 110565973
Intentional product misuse 62.36 18.29 104 22663 132800 110433732
Schizoaffective disorder 59.84 18.29 23 22744 3113 110563419
Muscle rigidity 59.34 18.29 45 22722 23986 110542546
Gliosis 58.80 18.29 16 22751 716 110565816
Irritability 58.36 18.29 60 22707 47749 110518783
Polyserositis 57.68 18.29 17 22750 1017 110565515
Head titubation 57.27 18.29 18 22749 1339 110565193
Myoclonus 56.64 18.29 50 22717 32948 110533584
Schizophrenia 56.40 18.29 42 22725 21784 110544748
Respiratory depression 55.95 18.29 49 22718 31952 110534580
Hepatic cytolysis 54.75 18.29 62 22705 54991 110511541
Abdominal discomfort 54.67 18.29 8 22759 393850 110172682
Peripheral swelling 54.29 18.29 9 22758 404025 110162507
Hypersensitivity 54.28 18.29 9 22758 403989 110162543
Ovarian failure 54.25 18.29 16 22751 960 110565572
Pruritus 54.22 18.29 26 22741 581534 109984998
Swelling 54.01 18.29 5 22762 351036 110215496
Choreoathetosis 53.30 18.29 18 22749 1680 110564852
Premature menopause 53.21 18.29 16 22751 1026 110565506
Encephalopathy 52.98 18.29 74 22693 80981 110485551
Tremor 52.02 18.29 123 22644 202109 110364423
Delirium 50.88 18.29 96 22671 134929 110431603
Hallucinations, mixed 50.81 18.29 28 22739 8665 110557867
Agranulocytosis 50.60 18.29 63 22704 61697 110504835
Rash 50.34 18.29 57 22710 820907 109745625
Persecutory delusion 50.31 18.29 25 22742 6266 110560266
Hepatocellular injury 50.30 18.29 57 22710 50585 110515947
Rheumatoid arthritis 49.69 18.29 3 22764 299610 110266922
Pouchitis 48.59 18.29 16 22751 1381 110565151
Antiphospholipid syndrome 46.34 18.29 18 22749 2505 110564027
Trismus 46.30 18.29 24 22743 6572 110559960
Headache 46.14 18.29 69 22698 882308 109684224
Hyperkinesia 45.63 18.29 19 22748 3165 110563367
Disorganised speech 44.96 18.29 19 22748 3284 110563248
Apraxia 43.69 18.29 19 22748 3521 110563011
Incorrect dose administered 43.23 18.29 77 22690 103564 110462968
Polydipsia 42.85 18.29 24 22743 7664 110558868
Depressed level of consciousness 42.51 18.29 80 22687 112198 110454334
Sinus tachycardia 40.70 18.29 48 22719 44445 110522087
Psychomotor retardation 39.86 18.29 23 22744 7769 110558763
Mutism 39.38 18.29 17 22750 3096 110563436
Somatic symptom disorder 39.14 18.29 17 22750 3142 110563390
Grandiosity 38.90 18.29 11 22756 568 110565964
Urticaria 38.83 18.29 9 22758 318848 110247684
Hypertension 38.82 18.29 29 22738 510055 110056477
Wheezing 38.30 18.29 4 22763 255226 110311306
Nasopharyngitis 37.70 18.29 17 22750 394344 110172188
Hepatic enzyme increased 37.25 18.29 10 22757 320882 110245650
Abnormal behaviour 37.18 18.29 43 22724 38996 110527536
Sinusitis 36.88 18.29 8 22759 296680 110269852
Stereotypy 36.80 18.29 12 22755 1005 110565527
Antisocial personality disorder 35.93 18.29 7 22760 67 110566465
Mood altered 35.91 18.29 32 22735 21343 110545189
Akathisia 35.67 18.29 29 22738 17084 110549448
Alcohol abuse 34.79 18.29 18 22749 4911 110561621
Proctectomy 34.57 18.29 9 22758 339 110566193
Cough 34.16 18.29 27 22740 461614 110104918
Cardio-respiratory arrest 33.70 18.29 74 22693 115762 110450770
Social anxiety disorder 33.34 18.29 11 22756 955 110565577
Hyperprolactinaemia 32.55 18.29 19 22748 6556 110559976
Torsade de pointes 32.46 18.29 31 22736 22569 110543963
Mental disorder 32.46 18.29 40 22727 38751 110527781
Withdrawal syndrome 32.32 18.29 36 22731 31344 110535188
Congenital cerebrovascular anomaly 31.95 18.29 5 22762 10 110566522
Vasoconstriction 31.85 18.29 11 22756 1099 110565433
Miosis 31.28 18.29 30 22737 21953 110544579
Manic symptom 31.08 18.29 8 22759 288 110566244
Drug intolerance 31.06 18.29 23 22744 406489 110160043
Back pain 31.02 18.29 19 22748 370977 110195555
Discomfort 30.63 18.29 4 22763 214703 110351829
Drug resistance 30.37 18.29 47 22720 56327 110510205
Speech disorder 29.96 18.29 49 22718 61520 110505012
Mucosal inflammation 29.78 18.29 63 22704 96078 110470454
Impaired healing 29.72 18.29 3 22764 196714 110369818
Floppy iris syndrome 29.66 18.29 8 22759 346 110566186
Paraesthesia 29.58 18.29 10 22757 276511 110290021
Lactate pyruvate ratio increased 29.56 18.29 6 22761 72 110566460
Affect lability 29.53 18.29 27 22740 18610 110547922
Torticollis 29.37 18.29 14 22753 3207 110563325
Bradyphrenia 29.03 18.29 22 22745 11706 110554826
Hallucination, tactile 28.89 18.29 10 22757 1005 110565527
Asthenia 28.67 18.29 62 22705 688937 109877595
Hypothermia 28.52 18.29 31 22736 26271 110540261
Blister 28.52 18.29 6 22761 227370 110339162
Dysarthria 28.26 18.29 57 22710 84064 110482468
Intentional product use issue 28.25 18.29 8 22759 247898 110318634
Electroconvulsive therapy 27.89 18.29 6 22761 97 110566435
Coordination abnormal 27.82 18.29 30 22737 25198 110541334
Crying 27.43 18.29 30 22737 25598 110540934
Paranoia 27.15 18.29 28 22739 22346 110544186
Wrong patient received product 27.14 18.29 17 22750 6657 110559875
Pericarditis 27.04 18.29 6 22761 219108 110347424
Asthma 26.86 18.29 9 22758 250282 110316250
Cardiac arrest 26.55 18.29 95 22672 196658 110369874
Contraindicated product administered 26.52 18.29 9 22758 248258 110318274
Cellulitis 26.47 18.29 71 22696 125945 110440587
Mobility decreased 26.44 18.29 8 22759 237414 110329118
Depressed mood 26.41 18.29 46 22721 60763 110505769
Restlessness 26.33 18.29 44 22723 56215 110510317
Peritonitis 26.28 18.29 33 22734 32574 110533958
Cerebral amyloid angiopathy 26.11 18.29 8 22759 547 110565985
Streptococcal infection 26.02 18.29 20 22747 10870 110555662
Oedema peripheral 25.88 18.29 18 22749 328642 110237890
Therapeutic product effect decreased 25.85 18.29 9 22758 244307 110322225
Loss of consciousness 25.83 18.29 94 22673 196212 110370320
Venous thrombosis limb 25.50 18.29 15 22752 5250 110561282
Self-injurious ideation 25.40 18.29 14 22753 4332 110562200
Blood citric acid increased 25.20 18.29 5 22762 53 110566479
Leukocytosis 25.06 18.29 42 22725 53786 110512746
Muscle spasms 25.03 18.29 13 22754 278144 110288388
Ileostomy closure 24.67 18.29 7 22760 366 110566166
Epileptic encephalopathy 24.45 18.29 8 22759 677 110565855
Poisoning 24.33 18.29 30 22737 29075 110537457
Chest pain 24.27 18.29 25 22742 376350 110190182
Intestinal obstruction 24.08 18.29 41 22726 53186 110513346
Abdominal pain upper 23.88 18.29 22 22745 349089 110217443
Acanthosis nigricans 23.61 18.29 6 22761 205 110566327
Pseudohallucination 23.50 18.29 6 22761 209 110566323
Hallucination 23.20 18.29 59 22708 101373 110465159
Blood cholesterol increased 22.92 18.29 5 22762 184780 110381752
Self-destructive behaviour 22.71 18.29 8 22759 847 110565685
Musculoskeletal stiffness 22.46 18.29 15 22752 279807 110286725
Hypoaesthesia 22.46 18.29 19 22748 314204 110252328
Lower respiratory tract infection 22.42 18.29 11 22756 243095 110323437
Lung disorder 22.07 18.29 5 22762 180042 110386490
Hyperammonaemia 21.96 18.29 20 22747 13712 110552820
Behaviour disorder 21.49 18.29 17 22750 9630 110556902
Onychophagia 21.41 18.29 5 22762 119 110566413
Long QT syndrome 21.36 18.29 15 22752 7103 110559429
Stomatitis 21.01 18.29 15 22752 270227 110296305
Parkinsonian gait 20.95 18.29 8 22759 1064 110565468
Status epilepticus 20.88 18.29 29 22738 31542 110534990
Dysphemia 20.87 18.29 12 22755 4025 110562507
Blood folate decreased 20.83 18.29 10 22757 2325 110564207
Abortion 20.81 18.29 9 22758 1645 110564887
Inflammation 20.64 18.29 7 22760 193231 110373301
Anticholinergic syndrome 20.22 18.29 12 22755 4268 110562264
Intracranial pressure increased 20.18 18.29 17 22750 10518 110556014
Gastrooesophageal reflux disease 20.15 18.29 6 22761 179970 110386562
Oedema 20.13 18.29 9 22758 209967 110356565
Cognitive disorder 20.11 18.29 51 22716 87460 110479072
Mental impairment 20.00 18.29 24 22743 22615 110543917
White blood cell count increased 19.77 18.29 54 22713 96788 110469744
Urinary retention 19.68 18.29 44 22723 69639 110496893
Hostility 19.47 18.29 10 22757 2686 110563846
Drug level increased 19.31 18.29 35 22732 47684 110518848
Illusion 19.15 18.29 9 22758 1998 110564534
Hiccups 19.14 18.29 18 22749 12851 110553681
Cogwheel rigidity 19.14 18.29 11 22756 3687 110562845
Drug screen false positive 19.05 18.29 8 22759 1361 110565171
Grimacing 18.84 18.29 7 22760 863 110565669
Eosinophilic myocarditis 18.82 18.29 9 22758 2076 110564456
General physical health deterioration 18.74 18.29 37 22730 425258 110141274
Faecaloma 18.71 18.29 19 22748 14889 110551643
Sudden death 18.57 18.29 24 22743 24371 110542161
Hallucination, visual 18.57 18.29 31 22736 39574 110526958
Intestinal anastomosis 18.31 18.29 7 22760 934 110565598

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AA01 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with aliphatic side-chain
FDA CS M0016525 Phenothiazines
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drug
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:76779 EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
CHEBI has role CHEBI:149553 anticoronaviral agent
MeSH PA D000932 Antiemetics
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014150 Antipsychotic Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018492 Dopamine Antagonists
FDA EPC N0000175746 Phenothiazine

Related Drugs by ATC class:

N05AA Phenothiazines with aliphatic side-chain 6 drugs
acepromazinechlorproethazinecyamemazinelevomepromazinepromazinetriflupromazine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Disruptive behavior disorder indication 54319003
Schizophrenia indication 58214004 DOID:5419
Psychotic disorder indication 69322001
Bipolar affective disorder, current episode manic indication 191618007
Acute intermittent porphyria indication 234422006 DOID:3890
Pre-Op Apprehension indication
Tetanus Adjunct Treatment indication
Intractable Hiccups indication
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 2.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.15 WOMBAT-PK CHEMBL
D(1A) dopamine receptor GPCR Ki 7.19 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.20 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.72 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.83 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 6.22 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 6.92 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 7.72 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.17 CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 8.10 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.28 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 7.40 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.44 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.41 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 9.55 PDSP
Alpha-2B adrenergic receptor GPCR Ki 7.60 WOMBAT-PK
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.54 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 6.93 WOMBAT-PK
Histamine H1 receptor GPCR Ki 8.20 WOMBAT-PK
Histamine H2 receptor GPCR Ki 6.76 PDSP
Histamine H4 receptor GPCR Ki 6.87 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 7.60 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 6.75 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 7.25 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 7.40 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 7.38 PDSP
Aldehyde oxidase Enzyme IC50 6.24 WOMBAT-PK
5-hydroxytryptamine receptor 1B GPCR Ki 5.83 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 6.35 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.10 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.68 DRUG MATRIX
Cytochrome P450 2D6 Enzyme Ki 5.16 WOMBAT-PK
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.69 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 8.71 DRUG MATRIX
5-hydroxytryptamine receptor 3A Ion channel Ki 6.01 PDSP
Alpha-1B adrenergic receptor GPCR Ki 9.09 PDSP
Kappa-type opioid receptor GPCR Ki 5.35 DRUG MATRIX
Calmodulin Cytosolic other Kd 5.91 CHEMBL
Delta-type opioid receptor GPCR Ki 5.13 DRUG MATRIX
5-hydroxytryptamine receptor 5A GPCR Ki 6.93 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 6.46 PDSP
Epidermal growth factor receptor Kinase IC50 4.54 DRUG MATRIX
Potassium channel subfamily K member 2 Ion channel IC50 5.57 CHEMBL
Tyrosine-protein kinase Fyn Kinase IC50 5.06 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 4.71 DRUG MATRIX
Ryanodine receptor 1 Ion channel IC50 3.57 WOMBAT-PK
Major prion protein Surface antigen EC50 5.70 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.57 CHEMBL
Substance-K receptor GPCR Ki 5.04 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.84 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 5.15 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.67 DRUG MATRIX
Solute carrier family 22 member 2 Transporter IC50 4.85 WOMBAT-PK
Lysine-specific histone demethylase 1A Enzyme IC50 5.29 CHEMBL
Glutamate [NMDA] receptor Ion channel IC50 6.22 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.37 CHEMBL
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.99 CHEMBL
Sphingomyelin phosphodiesterase Enzyme IC50 4.96 CHEMBL
Mu-type opioid receptor GPCR Ki 5.23 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.74 DRUG MATRIX
Trypanothione reductase Enzyme Ki 5.49 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 4.80 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 8.31 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.78 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 8.07 CHEMBL
Histamine H1 receptor GPCR Ki 7.30 CHEMBL
D(2) dopamine receptor GPCR Ki 8.92 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 6.75 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.68 CHEMBL
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 5.30 IUPHAR
D(1A) dopamine receptor GPCR Ki 7.46 CHEMBL
D(2) dopamine receptor GPCR IC50 7.10 CHEMBL
Transient receptor potential cation channel subfamily V member 1 Ion channel Ki 5.89 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 8.40 IUPHAR
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.35 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 5.89 CHEMBL
Glutamate NMDA receptor Ion channel IC50 5.89 CHEMBL
Muscarinic acetylcholine receptor GPCR Ki 7.22 CHEMBL
Dopamine receptor GPCR IC50 7.60 CHEMBL
Dopamine receptor GPCR Ki 7.85 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 9.15 CHEMBL
Adenylate cyclase Enzyme Ki 6.93 CHEMBL
Calmodulin Cytosolic other IC50 5.60 CHEMBL
Major prion protein Surface antigen EC50 5.70 CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 Enzyme IC50 4.64 CHEMBL

External reference:

IDSource
4017861 VUID
N0000146214 NUI
D00270 KEGG_DRUG
69-09-0 SECONDARY_CAS_RN
104728 RXNORM
C0008286 UMLSCUI
CHEBI:3647 CHEBI
Z80 PDB_CHEM_ID
CHEMBL71 ChEMBL_ID
CHEMBL1713 ChEMBL_ID
DB00477 DRUGBANK_ID
D002746 MESH_DESCRIPTOR_UI
2726 PUBCHEM_CID
83 IUPHAR_LIGAND_ID
183 INN_ID
U42B7VYA4P UNII
2140 MMSL
4264 MMSL
4428 MMSL
4429 MMSL
71853 MMSL
d00064 MMSL
001470 NDDF
004587 NDDF
387258005 SNOMEDCT_US
387479008 SNOMEDCT_US
47331002 SNOMEDCT_US
4017860 VANDF
4017861 VANDF
U42B7VYA4P INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9836 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9836 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2961 TABLET, COATED 10 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2962 TABLET, COATED 25 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2963 TABLET, COATED 50 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2964 TABLET, COATED 100 mg ORAL ANDA 14 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-2965 TABLET, COATED 200 mg ORAL ANDA 14 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-1397 INJECTION 25 mg INTRAMUSCULAR ANDA 17 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-1398 INJECTION 25 mg INTRAMUSCULAR ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-4027 CONCENTRATE 30 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-4028 CONCENTRATE 100 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6017 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6018 TABLET, FILM COATED 25 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6019 TABLET, FILM COATED 50 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6020 TABLET, FILM COATED 100 mg ORAL ANDA 17 sections
Chlorpromazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-6021 TABLET, FILM COATED 200 mg ORAL ANDA 17 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-047 TABLET, FILM COATED 10 mg ORAL ANDA 12 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-048 TABLET, FILM COATED 25 mg ORAL ANDA 12 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-049 TABLET, FILM COATED 50 mg ORAL ANDA 12 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-050 TABLET, FILM COATED 100 mg ORAL ANDA 12 sections
Chlorpromazine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-051 TABLET, FILM COATED 200 mg ORAL ANDA 12 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 31722-366 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
CHLORPROMAZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 31722-367 INJECTION 25 mg INTRAMUSCULAR ANDA 12 sections
CHLORPROMAZINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 43598-140 INJECTION 25 mg INTRAMUSCULAR ANDA 13 sections
CHLORPROMAZINE HCI HUMAN PRESCRIPTION DRUG LABEL 1 43598-141 INJECTION 25 mg INTRAMUSCULAR ANDA 13 sections
Chlorpromazine Human Prescription Drug Label 1 46708-735 TABLET 10 mg ORAL ANDA 13 sections
Chlorpromazine Human Prescription Drug Label 1 46708-736 TABLET 25 mg ORAL ANDA 13 sections
Chlorpromazine Human Prescription Drug Label 1 46708-737 TABLET 50 mg ORAL ANDA 13 sections
Chlorpromazine Human Prescription Drug Label 1 46708-738 TABLET 100 mg ORAL ANDA 13 sections
Chlorpromazine Human Prescription Drug Label 1 46708-739 TABLET 200 mg ORAL ANDA 13 sections